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Abstract
Background: The identification of transmission of variant Creutzfeldt-Jakob disease (vCJD) by blood transfusion has
prompted investigation to establish whether there has been any alteration in the vCJD agent following this route of
secondary transmission. Any increase in virulence or host adaptation would require a reassessment of the risk analyses
relating to the possibility of a significant secondary outbreak of vCJD. Since there are likely to be carriers of the vCJD agent
in the general population, there is a potential for further infection by routes such as blood transfusion or contaminated
surgical instruments.
Methodology: We inoculated both wild-type and transgenic mice with material from the first case of transfusion associated
vCJD infection.
Principal Findings: The strain transmission properties of blood transfusion associated vCJD infection show remarkable
similarities to the strain of vCJD associated with transmission from bovine spongiform encephalopathy (BSE).
Conclusions: Although it has been hypothesized that adaptation of the BSE agent through secondary passage in humans
may result in a greater risk of onward transmission due to an increased virulence of the agent for humans, our data
presented here in two murine models suggest no significant alterations to transmission efficiency of the agent following
human-to-human transmission of vCJD.
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Introduction
Variant Creutzfeldt-Jakob disease (vCJD) is an acquired form of
human transmissible spongiform encephalopathy (TSE) caused by
infection by the bovine spongiform encephalopathy (BSE) agent
that entered the human food chain in the United Kingdom during
the 1980s and early 1990s. [1,2] 164 cases of vCJD have been
identified in the United Kingdom and a further 41 cases in other
countries worldwide. Annual mortality rates indicate that the
vCJD outbreak is now in decline in the UK following a peak in
1999/2000. [3] In 2003 the first case of human-to-human
secondary transmission of vCJD via blood transfusion was
identified through a collaborative study between the UK National
Blood Services, the National CJD Surveillance Unit, and the
Office of National Statistics (Transfusion Medicine Epidemiology
Review, TMER). [4,5] Statistical analysis showed that the
possibility of this case being due to BSE infection was in the
order of 1:15,000 to 1:30,000. [4] This patient had received a
transfusion of non-leucodepleted red cells that had originated from
a donor who 3 years 4 months later developed clinical vCJD. The
blood recipient was methionine homozygous at codon 129 of the
prion protein (PrP) gene (PRNP), the same genotype as all tested
vCJD cases. [6]
Two further cases of vCJD linked to blood transfusion, in MM
genotype individuals, have subsequently been identified through
the TMER study. [7,8] Following the discovery of these cases
policy changes were made in relation to blood donation in the UK
and elsewhere. In 2004 the UK Blood Service deferred transfusion
recipients from acting as blood donors.
A fourth case, of asymptomatic infection following blood
transfusion, was described in 2004 and this individual was
heterozygous (MV) at codon 129. [9] This case was the first
indication that individuals with PRNP genotypes other than MM
could be infected by the vCJD agent. All three codon 129
genotypes are now thought to be susceptible to vCJD infection
following the identification of two VV genotype appendix tissues
positive for vCJD associated PrP (PrP
Sc) in an anonymous
screening study, and the successful transmission of vCJD to
‘humanised’ transgenic mice of each genotype. [10–12]
The implications of these findings are that a significant number
of the UK population may be carriers of vCJD infectivity, that
some of the individuals may be donating blood, and that not only
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this source. Our research in transgenic models indicates that MV
and VV individuals are likely to remain in an infectious preclinical
state for a significant period of time with incubation periods
potentially longer than average lifespan. [12] The identification of
four instances of secondary transmission of vCJD infection from a
group of 66 individuals known to have received blood products
from vCJD donors, including only 28 who survived at least five
years post transfusion indicates that blood transfusion is a
significant risk factor for vCJD. This is likely to be due to either
the route of transmission being more efficient of the agent being
more infectious on human-to-human transmission or a combina-
tion of both.
TSE transmission by the blood transfusion route has been
investigated in a sheep model. [13,14] These studies used
intravenous (i.v.) transfusion of whole blood and blood fractions
from clinical and preclinical sheep infected with BSE or scrapie.
Preliminary data showed that the i.v. route gave relatively short
and consistent incubation periods suggesting an efficient trans-
mission route, with success rates of 60% for sheep infected with
BSE and 40–45% for natural scrapie. [14,15]
Strain characterisation using a standard panel of inbred lines of
wild-type mice originally demonstrated that BSE and vCJD agents
had similar biological properties following transmission. [2,16]
Similar work in other murine models has also been undertaken to
study other human TSEs (genetic and iatrogenic CJD [17], and
sporadic CJD [2]), and has been used to examine emerging TSEs
(atypical BSE [18] and chronic wasting disease in deer and elk
[19]). [20] The development of transgenic mice expressing human
PrP has lead to further dissection of the nature of human TSE
strains, including transmission of vCJD to gene targeted human
transgenic mice. [12,17,21,22] Extensive data from studies in both
wild-type and transgenic models at the Neuropathogenesis
Division provide an essential background which will allow us to
identify any change in the transmission characteristics of vCJD
following secondary transmission. [2,12,23]
To investigate the nature of the transmissible agent following
secondary transmission from human-to-human following blood
transfusion we have examined the biological properties of brain
material from the first case of transfusion-associated vCJD
inoculated into panels of both wild-type, and transgenic mice
expressing human PrP.
Results
Clinical signs of a TSE in the transgenic mice were rare and
occurred after long incubation periods (IP) as found in our
previous study. [12] Inoculation of the vCJD (transfusion) case
produced one clinically positive HuMM mouse (at 659 days post
inoculation), two positive HuMV mice (at 596 and 638 dpi) and
no positive HuVV mice. Transmission of the vCJD (transfusion)
case to the RIII and VM lines showed extended incubation
periods compared to the three vCJD (BSE) cases. However, the
hierarchy of incubation periods in the two wild-type lines was
identical. (Figure 1 and Table 1) These data also show close
similarities to previously published vCJD (BSE) transmission to
wild-type mice despite different methodologies. These earlier
studies used cerebellar material for the inoculum which was
injected by simultaneous intracerebral and intraperitoneal routes.
[2,23,24]
The frequency of transgenic mice positive for TSE associated
vacuolation was similar between the vCJD (transfusion) case and
the published vCJD (BSE) case [12], with positive results in 8/15
HuMM, 0/17 HuMV, and 0/17 HuVV mice and 6/16 HuMM,
1/15 HuMV, and 1/15 HuVV mice respectively. Regional
distribution of TSE vacuolation in the brain was assessed through
lesion profiling. All wild-type and the HuMM transgenic lines had
sufficient positive mice to generate a profile (n$6 mice). The
overall pattern of the lesion profiles was the same in the vCJD
(transfusion) and vCJD (BSE) cases for all lines of mice, however,
Figure 1. Comparison of incubation periods in wild-type mice.
Incubation period plot comparison of vCJD (transfusion) case versus
transmissions in wild-type mice of vCJD (BSE) from three sources. (Data
shows mean incubation period6standard error of the mean. Open
circles RIII line and open triangles VM line.)
doi:10.1371/journal.pone.0002878.g001
Table 1. Clinical and pathological assessment of wild-type mice.
Inoculum Mouse Line Mice Inoculated
a
Positive for
Clinical TSE Signs
Positive for TSE
Vacuolation
Incubation Period
(days6SEM)
vCJD(BSE) A RIII 20 17 17 352.7669.78
vCJD(BSE) B RIII 20 18 17 374.3569.98
vCJD(BSE) C RIII 21 17 16 381.8866.07
vCJD (transfusion) RIII 23 18 18 477.33612.68
vCJD(BSE) A VM 22 15 22 510.20610.97
vCJD(BSE) B VM 22 20 21 523.75612.57
vCJD(BSE) C VM 21 13 18 530.6968.16
vCJD (transfusion) VM 22 15 18 572.90612.96
Wild-type mouse lines RIII and VM, inoculated with vCJD(BSE) and vCJD(transfusion) were assessed clinically and pathologically for signs of TSE and mean incubation
periods calculated.
aThe group of 24 was reduced due to unavailability of some brain material for analysis.
doi:10.1371/journal.pone.0002878.t001
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(Figure 2)
Immunocytochemical (ICC) detection of disease associated
abnormal PrP in paraffin sections was also used as a method of
assessing whether mice were transmission positive. There were 13/
14 HuMM, 8/17 HuMV, 1/17 HuVV positive mice in the vCJD
(transfusion) case, which was similar to the frequency of positives
in the published vCJD (BSE) case: 11/15 HuMM, 11/13 HuMV,
1/15 HuVV mice. ICC data can be used to show variation in
targeting of abnormal PrP deposition in the brain and variation in
the nature of deposits. The ICC pattern in transgenic mice
inoculated with the vCJD (transfusion) case matched that reported
for vCJD (BSE) [12]. The thalamus was specifically targeted with
deposition of abnormal PrP, and for the HuMM mice the
hippocampus contained many intensely stained plaques including
vCJD transmission associated florid plaques. ICC pattern in wild-
type mice also showed similarities between the data sets with
abnormal PrP deposition targeted to the thalamus and hippocam-
pus, and large aggregates in the white matter of the corpus
callosum. (Figure 3)
Biochemical analysis of disease-associated PrP by Western blot
can discriminate between human cases of vCJD and sporadic
CJD. [25] In the vCJD (transfusion) case the HuMM mice had a
type 2B gel mobility and glycoform ratio identical to that found in
vCJD (BSE) transmission to HuMM mice, and in vCJD itself.
(Figure 4) Brain tissue from both vCJD (transfusion) [4] and
published vCJD (BSE) [26] patients showed the type 2B pattern.
The levels of PrP
Sc seen in the HuMV and HuVV were too low to
allow typing by this standard Western blot method.
Discussion
Secondary passage of vCJD infection via blood transfusion in an
MM codon 129 genotype individual results in a clinical disease
phenotype and pathological characteristics that are similar to
vCJD derived from BSE. [4] In this paper we confirm that the
agent strain properties of primary and secondary vCJD cases are
similar in transmission studies in transgenic and wild-type mice.
Strain characteristics can be assessed by the frequency of clinical
signs in recipient animals, the incubation period, neuropatholog-
ical features, and PrP typing. All these parameters were similar in
the transmission studies of primary and secondary vCJD in
transgenic mice, indicating that the strain properties of the vCJD
agent have not changed significantly following secondary passage
in humans.
There were some differences in the results of the transmission
studies which deserve further comment. The incubation period in
wild-type mice was relatively extended in the vCJD(transfusion)
case. However, the hierarchy of incubation periods in different
inbred mouse strains was unchanged and the most plausible
explanation for these findings is that, rather than implicating a
change in agent characteristics, the titre of infectivity was less in
the brain sample from the vCJD(transfusion) case. The distribution
and degree of vacuolation was identical in the RIII mice. (Figure 2)
While the distribution was identical in the VM and HuMM mice
the degree of vacuolation intensity was lower for the vCJD(trans-
fusion) case. This variability could be due to the much longer
incubation times observed in these lines of mice or due to minor
changes of the strain properties.
Preliminary investigation of the individuals diagnosed with
vCJD following blood transfusion does not indicate a change in the
neuropathological characteristics of vCJD following secondary
transmission, although further studies are required to confirm this
observation.
The level of infectivity in peripheral tissues in secondary cases of
vCJD is unknown, although spleen and a lymph node were PrP
positive in the sub-clinical case linked to blood transfusion.
Evidence from BSE inoculation of primates indicates similar
peripheral distribution of disease associated PrP following either
oral or intravenous infection. [27] Further studies are required to
assess the anatomical distribution, strain properties and level of
infectivity in peripheral tissues in secondary vCJD infection. This
may be important for accurate assessment of the public health risks
associated with the potential for iatrogenic transmission of vCJD,
which are not solely defined by the agent characteristics in brain.
Blood transfusion appears to be a relatively efficient means of
secondary transmission of vCJD. To date, there have been four
such transmissions in a cohort of 28 individuals who survived at
least five years following transfusion of blood derived from
individuals incubating vCJD. Despite extensive exposure of the
UK population to the BSE agent in the food chain, there have
been a relatively limited number of primary cases of vCJD (164 in
the UK) and the outbreak has been in decline since 1999/2000.
An important question is why there should be a disparity in the
apparent efficiency of infection between primary and secondary
vCJD. Transmission is generally more efficient within species than
between species which may explain this observation. [28,29]
Inoculation of wild-type mice with material from primary and
secondary BSE passage in macaques showed that the BSE agent
retained a characteristic lesion profile even though the second
passage incubation period in the macaques was reduced by 50%.
[30] This suggests that efficiency of transmission may increase
without obvious changes to the agent strain.
Another factor is that the intravenous route of infection is very
much more efficient than the oral route, as shown in experimental
models. [27,31,32] Results from this study suggest the major factor
here is likely to be the route of infection rather than any changes in
the strain of agent. Future studies, including those using
experimental oral exposure to infectivity in transgenic mice, will
further address this issue.
All the primary and secondary clinical cases of vCJD have
occurred in individuals with a MM genotype. The sub- or pre-
clinical transfusion related infection was in a codon 129
heterozygote and genotyping of positive appendix samples
identified in a screening study confirmed valine homozygosity in
2 of 3 samples tested. [10] This indicates that individuals with all
codon 129 genotypes may be infected with the vCJD agent and the
effect of the MV or VV background on the characteristics of the
vCJD agent have not been addressed by the data in this paper.
In conclusion, transmission studies indicate that the strain
characteristics of vCJD have not been significantly altered by
secondary transmission through blood transfusion. This suggests
that the risk of onward transmission of vCJD through other routes,
for example contaminated surgical instruments, have not been
increased by adaptation of the infectious agent to humans
following secondary passage. However the characteristics of the
infectious agent in different genetic backgrounds has not yet been
defined and the prevalence of vCJD infection in the general
population remains uncertain. There is need to continue to
implement appropriate policies to protect against the risk of
secondary transmission of vCJD until many of the remaining
uncertainties are resolved.
Materials and Methods
The transgenic mice (HuMM, HuMV, HuVV) used in these
experiments have been described previously. [12] These mice
express human PrP under the regulation of the murine promoter
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mice of the same genetic background (129Ola) with no adverse
effects and no features of spontaneous TSE disease. Wild-type
mice (lines VM and RIII) are inbred lines used routinely for strain
typing of TSEs. RIII is a Prnp-a genotype line and VM is a Prnp-b
genotype line. [33] Use of mice for this work was reviewed and
approved by the Neuropathogenesis Division Ethics Committee
for Animal Experimentation.
Mice were inoculated as described previously. Groups of 24
wild-type mice received a 0.02 ml dose at 10
21 dilution by the
intracerebral route, for vCJD (transfusion) and vCJD (BSE).
Groups of 18 transgenic mice were injected with inoculum at a
higher dilution of 10
22 as in previous experiments more
concentrated inocula had been found to be toxic to the mice.
Inoculum was prepared as a homogenate in sterile saline from
frozen frontal cortex (with full consent from the patient’s relatives,
and approved by the Lothian NHS Board Research Ethics
Committee (Reference: 2000/4/157)) to allow accurate compar-
ison with previous data. Cases used for transmission were: the first
blood transfusion associated case, designated here as vCJD
(transfusion), and three historical vCJD cases designated here as
vCJD (BSE) A, B, and C. The historical vCJD cases were not
inoculated into the transgenic mice. Data from vCJD (transfusion)
inoculation of the transgenic mice was compared with that already
published for vCJD (BSE). [12] Data from vCJD (transfusion)
inoculation of the wild-type mice was compared with data from
the three historical vCJD cases.
Mice were housed in independently ventilated cages in a
Category 3 facility, monitored daily and scored for signs of TSE
disease weekly from 100 days post inoculation. Mice were culled,
when clinical TSE was evident or for animal welfare reasons, by
cervical dislocation and the brain bisected sagittally; one half
frozen for biochemical analysis of disease-associated prion protein
and the other half fixed in formalin for histology.
Vacuolation scoring was performed according to published
protocols and lesion profiles generated. [34,35] Immunocyto-
chemical detection of abnormal PrP deposition was performed as
published and Western blotting of disease-associated PrP from the
frozen half-brain carried out according to Head et al. [12,25]
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